摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-羟基苯酰肼 | 5818-06-4

中文名称
3-羟基苯酰肼
中文别名
M-羟基苯甲酰肼;3-羟基苯酰肼,98+%
英文名称
3-hydroxybenzoic hydrazide
英文别名
3-hydroxybenzohydrazide;3‑hydroxybenzohydrazide
3-羟基苯酰肼化学式
CAS
5818-06-4
化学式
C7H8N2O2
mdl
MFCD00014759
分子量
152.153
InChiKey
OACGSLLKFCMXSX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    158-161 °C (lit.)
  • 密度:
    1.318±0.06 g/cm3(Predicted)
  • 溶解度:
    溶于甲醇
  • 最大波长(λmax):
    251nm(MeOH)(lit.)
  • 稳定性/保质期:
    在常温常压下保持稳定

计算性质

  • 辛醇/水分配系数(LogP):
    -0.1
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    75.4
  • 氢给体数:
    3
  • 氢受体数:
    3

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 安全说明:
    S26,S36,S36/37/39
  • 危险类别码:
    R36/37/38
  • 海关编码:
    2928000090
  • WGK Germany:
    3
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    常温下应存于避光、阴凉干燥处,并密封保存。

SDS

SDS:3b7a6787d58cd7d248d88928e238ef31
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-Hydroxybenzohydrazide
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

Section 3. Composition/information on ingredients.
Ingredient name: 3-Hydroxybenzohydrazide
CAS number: 5818-06-4

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H8N2O2
Molecular weight: 152.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    3-羟基苯酰肼ammonium hydroxide 、 potassium hexacyanoferrate(III) 作用下, 生成 间羟基苯甲醛
    参考文献:
    名称:
    Kalb; Gross, Chemische Berichte, 1926, vol. 59, p. 733
    摘要:
    DOI:
  • 作为产物:
    描述:
    3-羟基苯甲酸乙酯 在 hydrazine hydrate 作用下, 以 乙醇 为溶剂, 生成 3-羟基苯酰肼
    参考文献:
    名称:
    合成新的基于x吨的类似物:其光学性质,千斤顶豆脲酶抑制作用和分子模型研究。
    摘要:
    在这项工作中,合成了一系列基于罗丹明6G的衍生物5a - 5g。通过使用1 H NMR,13 C NMR,FT-IR和LC-MS分析方法建立了合成化合物的结构框架。通过在四种不同溶剂中的吸收和荧光研究确定目标化合物的光谱性质。此外,对合成的衍生物进行了评估,以进行针对波克豆脲酶抑制作用的体外筛选和计算机分子对接研究。结果表明,所有化合物对这种酶均表现出良好的脲酶抑制活性,但在系列中,化合物5a和5c与IC 50值为4.7201±0.0546μM的标准药物(硫脲)相比,IC 50值为0.1108±0.0038μM和0.1136±0.0295μM的化合物显示出最大的吉祥抑制活性。随后,分析了分子对接实验以区分酶-抑制剂结合相互作用。
    DOI:
    10.1016/j.saa.2020.118667
点击查看最新优质反应信息

文献信息

  • Synthesis of novel 5-(aroylhydrazinocarbonyl)escitalopram as cholinesterase inhibitors
    作者:Mehr-un Nisa、Munawar A. Munawar、Amber Iqbal、Asrar Ahmed、Muhammad Ashraf、Qurra-tul-Ann A. Gardener、Misbahul A. Khan
    DOI:10.1016/j.ejmech.2017.06.036
    日期:2017.9
    A novel series of 5-(aroylhydrazinocarbonyl)escitalopram (58–84) have been designed, synthesized and tested for their inhibitory potential against cholinesterases. 3-Chlorobenzoyl- (71) was found to be the most potent compound of this series having IC50 1.80 ± 0.11 μM for acetylcholinesterase (AChE) inhibition. For the butyrylcholinesterase (BChE) inhibition, 2-bromobenzoyl- (76) was the most active
    已经设计,合成和测试了一系列新型的5-(芳酰基肼基羰基)依他普仑(58-84)对胆碱酯酶的抑制潜力。发现3-氯苯甲酰基- (71)是该系列中最有效的化合物,对乙酰胆碱酯酶(AChE)的抑制作用的IC 50为1.80±0.11μM。对于丁酰胆碱酯酶(BChE)抑制,2-溴苯甲酰基-(76)是该系列中活性最高的化合物,IC 50为2.11±0.31μM。构效关系说明温和的给电子基团增强了酶的抑制作用,而吸电子基团降低了除o -NO 2以外的抑制。然而,取代基的大小和位置影响酶抑制。。在AChE的对接研究中,配体71、72和76分别显示5874、5756和5666以及ACE的得分分别为-64.92,-203.25和-140.29 kcal / mol。在BChE的情况下,配体71、76和81分别显示出ACE值为-170.91,-256.84和-235.97 kcal / mol的高分6016、6150和5994。
  • Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof
    申请人:——
    公开号:US20020128292A1
    公开(公告)日:2002-09-12
    The present invention is directed to substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs thereof, represented by the general Formula I: 1 wherein X, Ar 1 , R 2 -R 6 and R 12 are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. The compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    本发明涉及取代的吲哚-2-羧酸亚苄基肼及其类似物,其由通式I表示: 1 其中X,Ar 1 ,R 2 -R 6 和R 12 的定义如本文中所述。本发明还涉及发现具有I式的化合物是半胱天冬酶的激活剂和凋亡的诱导剂。本发明的化合物可用于诱导在异常细胞不受控制的生长和扩散发生的多种临床状况中的细胞死亡。
  • ESTROGEN MODULATORS
    申请人:Bailey Simon
    公开号:US20070149564A1
    公开(公告)日:2007-06-28
    The present application is directed to a new class of isoxazoles and their use as estrogen modulators.
    本申请涉及一种新型异噁唑类化合物及其作为雌激素调节剂的用途。
  • 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
    申请人:GIOVANNINI Riccardo
    公开号:US20140045856A1
    公开(公告)日:2014-02-13
    The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    这项发明涉及一般式(I)的4-甲基-2,3,5,9,9b-五氮杂-环戊[α]萘衍生物,它们是磷酸二酯酶2和/或10的抑制剂,可用于治疗中枢神经系统疾病和其他疾病。此外,该发明涉及制备药物组合物的方法,以及根据该发明制造化合物的方法。
  • Tetraazabenzo[e]azulene derivatives and analogs thereof
    申请人:Elliott L. Richard
    公开号:US20050267100A1
    公开(公告)日:2005-12-01
    This invention relates to CCK-A agonists of Formula (I) wherein R 1 -R 4 , A, B, X, D, E and G are as defined in the specificiation, as well as, among other things, pharmaceutical compositions containing the compounds and methods of use of the compounds and compositions. The compounds are useful in treating obesity.
    这项发明涉及公式(I)中的CCK-A激动剂, 其中R1-R4,A,B,X,D,E和G如规范中所定义,以及包含这些化合物的药物组合物和这些化合物和组合物的使用方法。这些化合物在治疗肥胖症方面是有用的。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
mass
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐